[
    [
        {
            "time": "2018-01-04",
            "original_text": "复星医药(02196.HK)控股子公司获药品临床试验批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "控股子公司",
                    "药品",
                    "临床试验",
                    "批准"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药(02196.HK)控股子公司获药品临床试验批准",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "医疗保健：创新引领未来 荐6股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "创新",
                    "荐股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：创新引领未来 荐6股",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "又一新品种首家过评 乙肝一线药物过评企业达4家",
            "features": {
                "keywords": [
                    "新品种",
                    "首家过评",
                    "乙肝",
                    "一线药物",
                    "过评企业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "又一新品种首家过评 乙肝一线药物过评企业达4家",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]